Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 27;9(10):1473.
doi: 10.3390/children9101473.

Hypersensitivity to Intravenous Iron Preparations

Silvia Caimmi  1 , Giuseppe Crisafulli  2 , Fabrizio Franceschini  3 , Lucia Liotti  3 , Annamaria Bianchi  4 , Paolo Bottau  5 , Francesca Mori  6 , Paolo Triggiano  1 , Claudia Paglialunga  7 , Francesca Saretta  8 , Arianna Giannetti  9 , Giampaolo Ricci  10 , Carlo Caffarelli  11
Affiliations
Review

Hypersensitivity to Intravenous Iron Preparations

Silvia Caimmi et al. Children (Basel). .

Abstract

Intravenous iron is widely used for the treatment of iron deficiency anemia when adherence to oral iron replacement is poor. Acute hypersensitivity reactions during iron infusions are very rare but can be life threatening. Major risk factors for hypersensitivity reactions include a previous reaction to an iron infusion, a fast iron infusion rate, multiple drug allergies, atopic diseases, high serum tryptase levels, asthma, and urticaria. The management of iron infusions requires meticulous observation, and, in the event of an adverse reaction, prompt recognition and severity-related interventions by well-trained medical and nursing staff. Avoidance of IV iron products in patients with iron hypersensitivity reactions may not be considered as a standard practice.

Keywords: desensitization; drug allergy; drug provocation test; hypersensitivity reaction; iron; iron hypersensitivity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Iron–carbohydrate particles.
See this image and copyright information in PMC

References

    1. Auerbach M., Gafter Gvili A., Mac Dougall I.C. Intravenous iron: A framework for changing the management of iron deficiency. Lancet Hematol. 2020;7:e342–e350. doi: 10.1016/S2352-3026(19)30264-9. - DOI - PubMed
    1. Funk F., Fluhmann B., Barton A.E. Criticality of Surface Characteristics of Intravenous Iron–Carbohydrate Nanoparticle Complexes: Implications for Pharmacokinetics and Pharmacodynamics. Int. J. Mol. Sci. 2022;23:2140. doi: 10.3390/ijms23042140. - DOI - PMC - PubMed
    1. Gómez-Ramírez S., Shander A., Spahn D.R., Auerbach M., Liumbruno G.M., Vaglio S., Muñoz M. Management of acute intravenous iron reactions. Blood Transfus. 2019;17:137–145. - PMC - PubMed
    1. Chertow G.M., Mason P.D., Vaage-Nilsen O., Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol. Dial. Transplant. 2006;21:378–382. doi: 10.1093/ndt/gfi253. - DOI - PubMed
    1. Fortuny J., von Gersdorff G., Lassalle R., Linder M., Overbeek J., Reinold J., Toft G., Timmer A., Dress J., Blin P., et al. Use of intravenous iron and risk of anaphylaxis: A multinational observational post-authorisation safety study in Europe. Pharmacoepidemiol. Drug Saf. 2021;30:1447–1457. doi: 10.1002/pds.5319. - DOI - PMC - PubMed

LinkOut - more resources